Clinical Trials Logo

KRAS Wild Type clinical trials

View clinical trials related to KRAS Wild Type.

Filter by:
  • None
  • Page 1

NCT ID: NCT01351038 Terminated - Clinical trials for Resectable Type II Gastric Adenocarcinoma

Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma

Start date: n/a
Phase: Phase 2
Study type: Interventional

This is an open label, multicenter, single-arm phase II trial with primary eqirubicine-oxaliplatin-capecitabine chemotherapy and concurrent Pmab in patients with resectable, histologically proven gastric or esophageal cancer.